Clinical Report: The Rationale Behind Utilizing the Test-Negative Design for Ongoing Vaccine Surveillance

Overview

Wiegand et al. report interim estimates indicating that the updated COVID-19 vaccine reduced emergency department visits by 50% and hospitalizations by 55% in immunocompetent adults. The study utilizes the test-negative design to estimate vaccine effectiveness.

Background

The ongoing monitoring of vaccine effectiveness is crucial for public health decision-making, particularly in the context of COVID-19. The test-negative design (TND) offers a pragmatic approach to estimate vaccine effectiveness using observational data.

Data Highlights

Key Findings

• The updated COVID-19 vaccine reduced ED/UC encounters by 50% and hospitalizations by 55%.
• The test-negative design allows for effective estimation of vaccine effectiveness.
• Confounding by healthcare-seeking behavior is a potential bias in TND.
• Randomized clinical trials have limitations such as cost and complexity.
• Extensive sensitivity analyses are standard in TND studies.

Clinical Implications

Clinicians should be aware of the limitations and biases associated with observational studies while interpreting vaccine effectiveness data.

Conclusion

The test-negative design serves as a tool for estimating vaccine effectiveness.

Related Resources & Content

1. Wiegand et al., CDC, 2026 -- The Rationale Behind Utilizing the Test-Negative Design for Ongoing Vaccine Surveillance
2. Arshad et al., Drug Safety, 2023 -- Combining Epidemiological Approaches Sequentially Fails to Enhance Signal Detection in Vaccine Safety Monitoring
3. Arshad et al., Drug Safety, 2024 -- Discussion on 'The Impact of Sequential Epidemiological Approaches on Signal Detection in Vaccine Safety Monitoring'
4. Kaiser Family Foundation, KFF, 2026 -- Estimating Effectiveness of Influenza and COVID-19 Vaccines: The 'Test-Negative' Design
5. American Journal of Epidemiology, 2023 -- Examining Biases in Test-Negative Design Studies Assessing COVID-19 Vaccine Effectiveness Due to the Inclusion of Asymptomatic Cases
6. CDC, Vaccine Effectiveness | COVID-19
7. JAMA Internal Medicine, 2026 -- Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults
8. CDC Vaccine Effectiveness
9. Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults | Coronavirus (COVID-19) | JAMA Internal Medicine | JAMA Network